NeuBase Therapeutics (NASDAQ:NBSE) Sees Significant Decline in Short Interest

Share on StockTwits

NeuBase Therapeutics (NASDAQ:NBSE) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 133,700 shares, a decrease of 40.2% from the August 30th total of 223,400 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.2% of the company’s shares are short sold.

A number of research firms recently commented on NBSE. BTIG Research began coverage on NeuBase Therapeutics in a report on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price objective for the company. ValuEngine downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 5th.

Shares of NeuBase Therapeutics stock traded up $0.22 during trading hours on Friday, hitting $4.72. The company’s stock had a trading volume of 36,691 shares, compared to its average volume of 86,837. NeuBase Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.95.

NeuBase Therapeutics (NASDAQ:NBSE) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.

Further Reading: What is the formula for the cash asset ratio?

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.